ADVA-OPTICAL-NETWORKING
25.6.2020 09:02:04 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the Central Bank of Austria is deploying its FSP 3000 technology in a new, highly reliable, ultra-secure data center interconnect (DCI) network. With capacity for up to 32Gbit/s Fibre Channel and 100Gbit/s Ethernet services, the infrastructure provides robust, high-speed disaster recovery and business continuity capabilities that are essential for mission-critical operations. It’s protected by ADVA’s ConnectGuard™ Optical encryption and the real-time assurance of the ADVA ALM fiber monitoring solution. ADVA’s open modular FSP 3000 platform ensures that the bank’s redundant point-to-point system is easily scalable and highly efficient with space and power consumption. The network was installed by ADVA’s partners Componet and dacoso, who are also providing ongoing support with maintenance and SLA management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005079/en/
“Our customers demand world-class services with unbeatable security and availability. That’s why we’re committed to harnessing the most innovative technology on the market. Built on the ADVA FSP 3000 and secured by ConnectGuard™ Optical encryption, our new DCI network supports the fastest, most advanced SAN connectivity available, ensuring mission-critical data is always accessible and fully protected,” said Daniela Karanitsch, head of IT operations, Central Bank of Austria. “This flexible, high-capacity solution empowers us to tackle huge increases in data demand while also making significant savings on rack space and power consumption. What’s more, its efficiency and sustainability is further enhanced by ADVA’s ALM fiber monitoring technology, which provides round-the-clock visibility and assurance of the entire network.”
The Central Bank of Austria’s new network can transport up to 200Gbit/s on a single wavelength. It supports a wide range of services on one platform, including 1, 10, 25, 40 and 100Gbit/s Ethernet as well as 8, 16 and 32Gbit/s Fibre Channel. That flexibility enables the bank to maximize efficiency as it responds to changing customer requirements. Austria’s most sensitive financial data is now being safeguarded by encryption at the lowest network layer, guaranteeing resilient protection with none of the latency and performance problems that come with other security methods. ADVA’s FSP 3000 ConnectGuard™ Optical was the first encryption solution on the market to support Fibre Channel speeds up to 32Gbit/s. It’s still the only one capable of such speeds to achieve BSI-approved status, enabling its use for EU and NATO restricted data.
“Our FSP 3000 platform gives the Central Bank of Austria exceptionally fast, agile and robust disaster recovery and business continuity capabilities. And with our ALM technology, it delivers precise, real-time insight into the bank’s fiber plant so that any impairments or breaks can be rapidly repaired with minimal disruption. In fact, our ALM has already repaid the bank’s investment by identifying an issue at the service provider end and preventing outages from occurring,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “For a major national bank leasing dark fiber, secure connectivity is of paramount importance. With the low-latency, physical-layer encryption of our FSP 3000 ConnectGuard™, customers throughout Austria can now be sure of a frictionless experience and complete peace of mind when accessing their financial data.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005079/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom